Impact of type 2-targeted therapies on respiratory infection risk
T2-modulating biologics not only control allergic inflammation but also restore epithelial and immune homeostasis, contributing to maintained or reduced respiratory infection risk. These therapies represent a dual benefit of barrier repair and immune rebalancing. Further studies are warranted to evaluate long-term infection outcomes in high-risk populations.
Authors
- Kathryn Smiley
- Bob Geng
- N Zuhdi (ORCID: https://orcid.org/0009-0005-2659-7639)
Institutions
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- Riverside Community Hospital (US)
- Allergy and Asthma Medical Group and Research Center (US)
Publication Details
- Journal
- Current Opinion in Allergy and Clinical Immunology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1097/aci.0000000000001134
- Primary Topic
- Pediatric health and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00